Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 525

Similar articles for PubMed (Select 17329467)

1.

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA; CATIE Investigators.

Am J Psychiatry. 2007 Mar;164(3):428-36.

PMID:
17329467
2.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators; Neurocognitive Working Group.

Arch Gen Psychiatry. 2007 Jun;64(6):633-47.

PMID:
17548746
3.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):600-10.

PMID:
16585434
4.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2007 Mar;164(3):415-27.

PMID:
17329466
5.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):611-22.

PMID:
16585435
6.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

7.

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators.

Am J Psychiatry. 2006 Dec;163(12):2080-9.

PMID:
17151158
8.

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA.

Am J Psychiatry. 2007 Jul;164(7):1061-71.

PMID:
17606658
9.

Effectiveness of switching antipsychotic medications.

Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA.

Am J Psychiatry. 2006 Dec;163(12):2090-5.

PMID:
17151159
10.

What CATIE found: results from the schizophrenia trial.

Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA.

Psychiatr Serv. 2008 May;59(5):500-6. doi: 10.1176/appi.ps.59.5.500.

PMID:
18451005
11.

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA.

Schizophr Bull. 2003;29(1):15-31.

12.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.

Psychopharmacology (Berl). 2007 Dec;195(2):285-95. Epub 2007 Aug 14.

PMID:
17701027
13.

[Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].

Mayoral F, Montejo AL, Bousoño M, González-Torres MA, Olivares JM, Ros S, Sanjuán J, Escobar R, Lara N.

Actas Esp Psiquiatr. 2006 Jan-Feb;34(1):7-15. Spanish.

PMID:
16525900
14.

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA; CATIE Investigators.

Schizophr Res. 2008 Mar;100(1-3):39-52. doi: 10.1016/j.schres.2007.11.034. Epub 2008 Jan 11.

PMID:
18191383
15.

Results of phase 3 of the CATIE schizophrenia trial.

Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK; CATIE Investigators.

Schizophr Res. 2009 Jan;107(1):1-12. doi: 10.1016/j.schres.2008.10.011. Epub 2008 Nov 21.

16.

Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.

Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, Fernando ML, Senthilal S.

Schizophr Res. 2007 Nov;96(1-3):146-55. Epub 2007 Aug 29.

PMID:
17728106
17.

Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.

Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.

J Clin Psychiatry. 2008 Dec;69(12):1901-15. Epub 2008 Sep 9.

PMID:
19012820
18.

Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.

Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S.

J Clin Psychopharmacol. 2006 Oct;26(5):453-61. Erratum in: J Clin Psychopharmacol. 2009 Apr;29(2):169.

PMID:
16974184
19.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA.

Am J Psychiatry. 2002 Jun;159(6):1018-28.

PMID:
12042192
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk